Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva.
Malignant tumors of the vulva, most of them squamous cell carcinomas, account for only 5% of cancers of the female genital tract. Though little is known about the genetic features of these tumors, the Fragile Histidine Triad (FHIT) and High Mobility Group AT-hook 2 (HMGA2) genes were found deregulated. We wanted to gain more knowledge about the expression of HMGA2-related miRNAs such as miR-30c and let-7a, and whether a correlation exists between the expression of FHIT and HMGA2, in this tumor type. An inverse correlation was found in-as-much as HMGA2 was highly expressed (mean fold change 8.8) whereas miR30c and let-7a were both downregulated (mean fold change -3.9 and -2.3, respectively). The consistent overexpression of HMGA2 found in all tumors adds to the likelihood that this gene is of importance in SCC pathogenesis. Moreover, we came to the conclusion that miRNAs may be the cause of the deregulation of HMGA2. Our results also show that SCC of the vulva presents a characteristic molecular pattern with FHIT being downregulated whereas HMGA2 is upregulated.
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.|Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Antonio
A
Agostini
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.|Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Marta
M
Brunetti
Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.|Faculty of Medicine, University of Oslo, Oslo, Norway.
Ben
B
Davidson
Department of Gynecology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Claes G
CG
Trope
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.|Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.|Faculty of Medicine, University of Oslo, Oslo, Norway.
Sverre
S
Heim
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.|Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Ioannis
I
Panagopoulos
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.|Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Francesca
F
Micci
D017766:Acid Anhydride Hydrolases / Q000235:genetics* / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D025743:HMGA2 Protein / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D015854:Up-Regulation; D014844:Vulva / Q000473:pathology*; D014846:Vulvar Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000099170:Bis(5'-adenosyl)triphosphatase
D017766:Acid Anhydride Hydrolases; D025743:HMGA2 Protein; D035683:MicroRNAs; D009363:Neoplasm Proteins; D000099170:Bis(5'-adenosyl)triphosphatase; C546086:MIRN30b microRNA, human; C487931:mirnlet7 microRNA, human
FHIT; HMGA2; let-7a; miR-30c